Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $135M Series B led by Sanofi Ventures and EQT (Jun 2025). First patient dosed in Phase 1/2 for Stargardt disease (Jan 2026). Overcomes 4.7kb AAV cargo limit.
SpliceBio is a gene therapy company whose protein trans-splicing platform overcomes the 4.7-kilobase cargo limit of adeno-associated viral (AAV) vectors — the primary delivery vehicle for gene therapy — unlocking treatments for large-gene diseases previously untreatable. The company raised $135 million in Series B financing co-led by Sanofi Ventures and EQT Life Sciences in June 2025, and dosed its first patient in Phase 1/2 Part B for SB-007 in Stargardt disease in January 2026.
Raised $900M Series E at $11B valuation (Oct 2025). CEO projects ~$2B in 2026 sales. Launched women's health LLM (Feb 2026). Team USA LA28 Olympic partner.
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E financing at an $11 billion valuation in October 2025, reflecting the doubling of its revenue to $500 million in 2024 and a projected $1.5–2 billion in 2026 sales as it expands global distribution into India, UAE, and Latin America.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.